The formation of a Scientific Advisory Board is a strategic move that often signals to investors and the market that a company is serious about advancing its product development. By leveraging the expertise of the board, Moleculin could accelerate Annamycin's development, potentially leading to positive clinical trial results or strategic partnerships. This development is likely to be viewed positively by investors, as it could reduce the time to market and increase the likelihood of success for Annamycin, thereby potentially enhancing MBRX's stock value in the short term.